<DOC>
	<DOCNO>NCT00986154</DOCNO>
	<brief_summary>Evaluation heparin/edoxaban tosylate ( DU176b ) versus heparin/warfarin prevent recurrence blood clot patient acute symptomatic deep-vein blood clot legs and/or blood clot lung .</brief_summary>
	<brief_title>Comparative Investigation Low Molecular Weight ( LMW ) Heparin/Edoxaban Tosylate ( DU176b ) Versus ( LMW ) Heparin/Warfarin Treatment Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots . ( The Edoxaban Hokusai-VTE Study ) .</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Male female subject older minimum legal adult age ( country specific ) ; Acute symptomatic proximal DVT and/or symptomatic PE confirm site appropriate diagnostic imaging ; Able provide write informed consent thrombectomy , insertion caval filter , use fibrinolytic agent treat current episode DVT and/or PE ; More 48 hour pretreatment anticoagulant therapy prior randomization ; Calculated Creatinine clearance ( CrCL ) &lt; 30 mL/min ; significant liver disease ( e.g. , acute hepatitis , chronic active hepatitis , cirrhosis ) alanine transaminase ( ALT ) &gt; \= 2 time upper limit normal ( ULN ) , total bilirubin ( TBL ) x 1.5 time ULN ; patient active cancer long term treatment ( LMW ) heparin anticipate ; active bleeding high risk bleed contraindicate treatment ( LMW ) heparin warfarin ; chronic treatment nonaspirin nonsteroidal antiinflammatory drug ( NSAIDs ) ; treatment aspirin dosage 100 mg/per day dual antiplatelet therapy ; concurrent treatment potent Pgp inhibitor ; subject condition , judge investigator , would place subject increase risk harm he/she participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Recurrent Thrombosis</keyword>
	<keyword>Recurrent Pulmonary Embolism</keyword>
	<keyword>Symptomatic Deep Vein Thrombosis</keyword>
	<keyword>Symptomatic Pulmonary Embolism</keyword>
	<keyword>Venous Thromboembolism ( VTE )</keyword>
</DOC>